HC Wainwright Issues Negative Forecast for TSE:FRX Earnings

Key Points

• HC Wainwright cut its Q3 2026 EPS estimate for Fennec to $0.17 (from $0.26) and provided updated estimates including FY2027 EPS of $1.33.
• Despite the revision, B. Riley upgraded Fennec to a "strong-buy" and the stock carries a consensus rating of Strong Buy on MarketBeat.
• Shares opened at C$8.33 with a 12‑month range of C$7.02–C$13.83, a market cap of C$284.58M, a negative P/E of -23.80 and a beta of 3.01; an insider sold 10,349 shares while insiders still own 16.20% of the company.

Fennec Pharmaceuticals Inc. (TSE:FRX - Free Report) - Research analysts at HC Wainwright dropped their Q3 2026 earnings per share (EPS) estimates for Fennec Pharmaceuticals in a report issued on Monday, March 30th. HC Wainwright analyst R. Selvaraju now anticipates that the biopharmaceutical company will post earnings per share of $0.17 for the quarter, down from their previous forecast of $0.26. The consensus estimate for Fennec Pharmaceuticals' current full-year earnings is $0.60 per share. HC Wainwright also issued estimates for Fennec Pharmaceuticals' Q4 2026 earnings at $0.22 EPS, Q3 2027 earnings at $0.36 EPS, Q4 2027 earnings at $0.42 EPS and FY2027 earnings at $1.33 EPS.

Separately, B. Riley Financial upgraded shares of Fennec Pharmaceuticals to a "strong-buy" rating in a research note on Wednesday, February 11th. One investment analyst has rated the stock with a Strong Buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of "Strong Buy".

Fennec Pharmaceuticals Price Performance

Shares of Fennec Pharmaceuticals stock opened at C$8.33 on Tuesday. The business has a 50-day moving average of C$10.57 and a 200 day moving average of C$11.14. Fennec Pharmaceuticals has a 12 month low of C$7.02 and a 12 month high of C$13.83. The stock has a market capitalization of C$284.58 million, a price-to-earnings ratio of -23.80 and a beta of 3.01.

Insider Buying and Selling at Fennec Pharmaceuticals

In other news, Director Rostislav Christov Raykov sold 10,349 shares of the company's stock in a transaction on Monday, February 2nd. The stock was sold at an average price of C$10.69, for a total transaction of C$110,630.81. Following the sale, the director owned 2,709,294 shares of the company's stock, valued at approximately C$28,962,352.86. This represents a 0.38% decrease in their ownership of the stock. Corporate insiders own 16.20% of the company's stock.

Fennec Pharmaceuticals Company Profile

Fennec Pharmaceuticals Inc is a clinical-stage biotechnology company. It is primarily engaged in research and development activities. The company is developing Sodium Thiosulfate (STS), a chemo-protectant against hearing loss associated with platinum-based chemotherapy. Its lead product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin induced hearing loss, or ototoxicity in children.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.